Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

1-41-66 (USA)

The conference call (Call ID 204, followed by the #) will be available for play-back for 48 hours after the call by dialling:
+41-(0)91-612-43-30 (Europe)

+44-(0)207-108-62-33 (UK)

+1-(1)866-416-25-58 (USA)

About Arpida Ltd. Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed four Phase I trials. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015   ... für Diagnostik und Therapie, Strahlendosismanagement und IT-Lösungen für ... Royal Philips (NYSE: PHG, AEX: PHIA) ... 2015 (ECR) bekannt, der vom 4. bis 8. März ... den Ständen Nr. 102 and 110 ...
(Date:3/3/2015)... Experts and industry insiders from around the world ... REBELation exploring innovation, inspiration and world-changing ideas in Lexington, ... year, Alltech’s annual international conference traditionally draws more than ... join the REBELation at an extra discount registration closes ... which point the standard early registration rate will apply. ...
(Date:3/3/2015)... , March 3, 2015 /CNW/- SQI Diagnostics Inc. ... commercializes proprietary technologies and products for advanced microarray ... CPA, CA, CFE  to its Management team. In ... Company in its transition from a development stage ... initiatives to advance the Company,s capital market strategy ...
(Date:3/3/2015)... 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... development of and commercialization of regenerative cell therapies to ... today that it has received the final payment to ... Inc. (OTC Bulletin Board: AMBS ). ... the final payments due to Regenicin in the amount ...
Breaking Biology Technology:Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3
... everywhere from the air we breathe and the food we ... innocuous or even beneficial, and only a handful pose any threat ... intruder? , Research from the University of Wisconsin-Madison suggests the ... A study appearing online this week in the Proceedings of ...
... the United ... States and Canada, INDIANAPOLIS, ... partnership that will allow Roche to market,the first line of cardiovascular ... 200 (Rapid Analyte Measurement Platform), is,based on RAMP technology that is ...
... Calif., July 28 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... Kiwa Bio-Tech Products (Shandong) Co., Ltd. (Kiwa ... million (over US$21,million) with Jilin Tianma Science ... distributors. Delivery of products under these contracts ...
Cached Biology Technology:Symbiotic microbes induce profound genetic changes in their hosts 2Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 2Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 3Kiwa Bio-Tech Signs RMB 150 Million (US$21+ million) Fertilizer Contract 2Kiwa Bio-Tech Signs RMB 150 Million (US$21+ million) Fertilizer Contract 3
(Date:2/24/2015)... 24, 2015 Research and Markets ... the "Global 2D Gesture Recognition Market 2015-2019" ... The analysts forecast the Global 2D Gesture Recognition ... over the period 2014-2019 The increased ... is one of the major trends in the ...
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
(Date:2/10/2015)... -- Alere Inc. (NYSE: ALR), a global leader in ... quarter ended December 31, 2014. Namal ... said, "We made substantial progress in the fourth ... in rapid diagnostics and delivering against our financial ... early January enabled us to substantially reduce our ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... invasive species of plant called common reed, grows rapidly into ... to Great Lakes coastal wetlands. Early treatment is the key ... invasive reeds be eradicated before they take over their environment ... do know, thanks to scientists from Michigan Technological University,s Michigan ...
... snackers? A new Cornell study finds that serving children combined ... fewer calories and be just as satisfied as those who ... eat, and they take longer to eat than potato chips. ... so much less," said Brian Wansink, professor of marketing at the ...
... Center and the Moffitt Cancer Center, led by Dr. ... imaging (MRI) method can non-invasively evaluate the cellular proliferation ... imaging method evaluates the diffusion of water in tumor ... tumor models. The results, which appear in the November ...
Cached Biology News:Following Phragmites home 2Combo-snacks of cheese and vegetables cut kids calories 2
... cells were cultured in Ham's F12K medium with ... phase of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
CELLine System cultivation flask (for secreted products)...
... K28/86.2, PDZ Domain GenBank Accession ... GST fusion to residues 77-299 of ... pH 7.4, 0.075M NaCl containing 0.05% ... by immunoblot on rat brain microsomal ...
... western blots ,• Optically clear plastic construction ... western blots. The reduced size (60 x ... tray requires less dye and antibodies resulting ... user. Pour spouts in each corner facilitate ...
Biology Products: